Volume 20, Number 6—June 2014
Research
Characteristics of Patients with Mild to Moderate Primary Pulmonary Coccidioidomycosis
Table 2
Comparison of onset of symptoms to time to study end points among 36 patients with primary pulmonary coccidioidomycosis, Arizona, USA, March 1, 2010– October 31, 2012*
Study end point | Antifungal treatment |
p value | |||
---|---|---|---|---|---|
Yes, n = 20 | No, n = 16 | ||||
Time to 50% reduction in symptom score, wk | 0.84† | ||||
Median | 9.9 | 9.1 | |||
Q1, Q3 | 7.0, 13.4 | 7.4, 17.1 | |||
Range |
4.0–24.0 |
3.7–24.4 |
|||
Time to complete symptom resolution, wk | 0.65‡ | ||||
Median | 18.7 | 17.8 | |||
Q1, Q3 | 13.6, 25.0 | 12.1, 24.0 | |||
Range |
8.9–29.6 |
8.7–27.1 |
|||
Time to 50% reduction in fatigue, wk§ | 0.59‡ | ||||
Median | 12.9 | 9.8 | |||
Q1, Q3 | 8.0, 16.0 | 8.4, 15.9 | |||
Range |
5.0–29.6 |
4.4–25.6 |
|||
Time to full attendance at work, wk | 0.02† | ||||
Median | 8.4 | 5.7 | |||
Q1, Q3 | 6.7, 14.8 | 5.1, 6.0 | |||
Range |
9.0–29.6 |
2.4–7.6 |
|||
Time to full attendance at school, wk | |||||
Median | 13.7 | ||||
Q1, Q3 |
13.7, 13.7 |
||||
Time to 50% improvement in PCS, wk | 0.08‡ | ||||
Median | 20.4 | 13.8 | |||
Q1, Q3 |
14.7, 26.0 |
10.4, 18.0 |
|||
Time to 50% improvement in MCS, wk | 0.21‡ | ||||
Median | 12.0 | 8.1 | |||
Q1, Q3 | 9.3, 14.7 | 6.6, 9.7 |
*Q1, first quartile; Q3, third quartile; PCS, physical activity score as measured on the SF-36 General Health Survey; MCS, mental activity score as measured on the SF-36 General Health Survey.
†By the Wilcoxon rank–sum test.
‡By the equal variance t test.
§As reported on the Fatigue Severity Scale.